We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

112 hedge funds and large institutions have $81.8M invested in Lyell Immunopharma in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

7% more funds holding

Funds holding: 105 → 112 (+7)

0.01% more ownership

Funds ownership: 2.57% → 2.58% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

15% less capital invested

Capital invested by funds: $95.9M → $81.8M (-$14.1M)

33% less call options, than puts

Call options by funds: $2K | Put options by funds: $3K

36% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 36

Holders
112
Holders Change
+7
Holders Change %
+6.67%
% of All Funds
1.5%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
14
Increased
23
Reduced
36
Closed
7
Calls
$2K
Puts
$3K
Net Calls
-$1K
Net Calls Change
-$2K

Top Buyers

1
FCMI
Foresite Capital Management IV
California
+$4.71M
2
AC
Almitas Capital
California
+$877K
3
Citadel Advisors
Citadel Advisors
Florida
+$461K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$272K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$160K

Top Sellers

1
O
OrbiMed
New York
-$1.99M
2
Millennium Management
Millennium Management
New York
-$560K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$545K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$506K
5
UBS Group
UBS Group
Switzerland
-$462K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
76
Royal Bank of Canada
Ontario, Canada
$11K -$2.33K -190 -16%
Fidelity Investments
77
Fidelity Investments
Massachusetts
$10.4K +$1.99K +162 +20%
HSBC Holdings
78
HSBC Holdings
United Kingdom
$9.67K -$74 -6 -0.6%
AIP
79
Ameritas Investment Partners
Nebraska
$9.21K – – –
IC
80
IEQ Capital
California
$8.82K +$10K +820 New
Victory Capital Management
81
Victory Capital Management
Texas
$8.15K -$1.65K -135 -15%
Legal & General Group
82
Legal & General Group
United Kingdom
$8.07K – – –
Dimensional Fund Advisors
83
Dimensional Fund Advisors
Texas
$7.24K – – –
GS
84
GTS Securities
New York
$7.02K +$7.99K +652 New
AP
85
Adero Partners
California
$7.02K – – –
Cerity Partners
86
Cerity Partners
New York
$6.84K +$7.78K +635 New
Wealth Enhancement Advisory Services
87
Wealth Enhancement Advisory Services
Minnesota
$6.78K +$7.72K +630 New
FCM
88
Fortis Capital Management
Washington
$6.51K – – –
California State Teachers Retirement System (CalSTRS)
89
California State Teachers Retirement System (CalSTRS)
California
$6.26K – – –
AAM
90
Advisors Asset Management
Colorado
$6.25K +$7.12K +581 New
AHL
91
Abel Hall LLC
Louisiana
$6.14K +$7K +571 New
X
92
Xponance
Pennsylvania
$6.06K +$159 +13 +2%
Mackenzie Financial
93
Mackenzie Financial
Ontario, Canada
$6.03K – – –
Carson Wealth (CWM LLC)
94
Carson Wealth (CWM LLC)
Nebraska
$6K +$5.56K +454 +366%
Principal Financial Group
95
Principal Financial Group
Iowa
$5.92K – – –
RC
96
Rangeley Capital
Connecticut
$5.38K +$6.13K +500 New
Mirae Asset Global Investments
97
Mirae Asset Global Investments
South Korea
$5.29K +$294 +24 +5%
Group One Trading
98
Group One Trading
Illinois
$3.23K +$2.45K +200 +200%
SAM
99
Shell Asset Management
Netherlands
$3K -$3.93K -321 -50%
AB
100
Amalgamated Bank
New York
$3K – – –
1 2 3
4
5

LYEL Hedge Fund Activity: Q1 2025 in Review

112 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q1 2025, worth a combined $81.8M — down 15% from $95.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LYEL positions and 7 closed out — a net gain of 7 holders — while 23 added to existing stakes and 36 trimmed.

The largest buyer was Foresite Capital Management IV, adding an estimated $4.71M. The largest seller was OrbiMed, exiting entirely with an estimated $1.99M sold.

  • 112 institutional investors held Lyell Immunopharma (LYEL) as of Q1 2025, up from 105 in Q4 2024.
  • Funds reported $81.8M of Lyell Immunopharma stock for Q1 2025, down 15% quarter-over-quarter.
  • 14 funds opened new Lyell Immunopharma positions in Q1 2025 and 7 closed out, a net change of +7 holders.
  • The largest Lyell Immunopharma buyer in Q1 2025 was Foresite Capital Management IV, an estimated $4.71M added.
  • The largest Lyell Immunopharma seller in Q1 2025 was OrbiMed, an estimated $1.99M sold.

Based on aggregated 13F filings for Q1 2025.